The objectives are to: 1. validate a panel of tissue-specific miRNAs that are differentially expressed in the tissue of patients with and without reactive hyperplasia and lymphoma. 2. investigate the physiological range of the miRNA panel in lymphoma and reactive hyperplasia subjects. 3. investigate the dysregulation of miRNA panel and their prognostic and predictive values in clinical outcomes to identifying patients with malignant lymphoma or reactive hyperplasia. The objectives are to: 1. validate a panel of tissue-specific miRNAs that are differentially expressed in the tissue of patients with and without reactive hyperplasia and lymphoma. 2. investigate the physiological range of the miRNA panel in lymphoma and reactive hyperplasia subjects. 3. investigate the dysregulation of miRNA panel and their prognostic and predictive values in clinical outcomes to identifying patients with malignant lymphoma or reactive hyperplasia. This trial involves tissue samples diagnosed as lymphoma and reactive hyperplasia. The investigators will develop panels of miRNAs that are specific biomarkers of lymphoma, and assist clinical outcomes with these miRNAs.
Study Type
OBSERVATIONAL
Enrollment
200
University of Electronic Science and Technology of China
Chengdu, Sichuan, China
RECRUITINGThe concentration of miRNA expression quantitated in absolute copy numbers and their correlation in patients with reactive hyperplasia and lymphoma.
The concentration of tissue miRNAs in absolute quantification in comparison to reactive hyperplasia and lymphoma. To investigate the potential prognosis of lymphoma by the expression difference of the miRNA panel. Sensitivity, specificity and the potential scopes of selected miRNA in the miRNA panel to distinguish hyperplasia and lymphoma and against standard clinical outcome.
Time frame: Three years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.